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Abstract
Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) 
syndrome is a newly characterized autoinflammatory disorder, caused by mutations in PSMB8. It 
is characterized by early-onset fevers, accompanied by a widespread, violaceous and often 
annular, cutaneous eruption. While the exact pathogenesis of this syndrome is still obscure, it is 
postulated that the inflammatory disease manifestations stem from excess secretion of interferons. 
Based on preliminary blood cytokine and gene expression studies, the signature seems to come 
mostly from type I interferons, which are proposed to lead to the recruitment of immature myeloid 
cells into the dermis and subcutis. In this study, we systematically analyzed skin biopsies from 6 
CANDLE syndrome patients by routine histopathology and immunohistochemistry methods. Skin 
lesions showed the presence of extensive mixed dermal and subcutaneous inflammatory infiltrate, 
composed of mononuclear cells, atypical myeloid cells, neutrophils, eosinophils and some mature 
lymphocytes. Positive LEDER and myeloperoxidase staining supported the presence of myeloid 
cells. Positive CD68/PMG1 and CD163 staining confirmed the existence of histiocytes and 
monocytic macrophages in the inflammatory infiltrate. CD123 staining was positive, 
demonstrating the presence of plasmacytoid dendritic cells. Uncovering the unique histopathologic 
Author for correspondence: Antonio Torrelo, MD, Department of Dermatology, Hospital del Niño Jesús, Menéndez Pelayo 65, 
28009-Madrid, Spain, atorrelo@aedv.es. 
Conflicts of Interest
For the remaining authors no conflicts of interest or funding are declared.
HHS Public Access
Author manuscript
Am J Dermatopathol. Author manuscript; available in PMC 2016 July 01.
Published in final edited form as:









and immunohistochemical features of CANDLE syndrome provides tools for rapid and specific 
diagnosis of this disorder as well as further insight into the pathogenesis of this severe, life-
threatening condition.
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INTRODUCTION
Chronic, atypical, neutrophilic dermatosis with lipodystrophy and elevated temperature 
(CANDLE) syndrome1,2 is a newly characterized autosomal recessive autoinflammatory 
disease caused by mutations in PSMB8, which encodes the inducible β5i subunit of the 
immunoproteasome.3 Patients present with recurrent fevers and skin lesions beginning in 
early infancy. The skin lesions are characterized by recurrent and overlapping attacks of 
annular, erythematous or violaceous plaques that heal with residual purpura. With time, 
persistent violaceous edema develops around the eyelids and mouth. Recurrent episodes of 
multi-organ inflammation, as well as persistent, subclinical background inflammation, lead 
to delayed growth. Additionally, patients develop facial lipodystrophy and prominent 
abdomen, thus conferring the patients a very characteristic clinical phenotype.
The fact that the skin lesions of CANDLE syndrome appear during the first weeks or months 
of life allow for an early diagnosis of this progressive disorder. Furthermore, histopathology 
of the skin changes on light microscopy demonstrate characteristic features.1 There is a 
dense interstitial dermal infiltrate, extending into the subcutis, composed of mononuclear 
cells, many of them with atypical features exhibiting a myeloid appearance with bizarre 
nuclei, as well as neutrophils, which in some areas undergo karyorrhexis. However, the 
exact nature and origin of the atypical mononuclear cells in CANDLE syndrome have not 
been analyzed in detail. Thus, we performed an immunohistochemistry (IHC) study in skin 
biopsies from 6 patients with CANDLE syndrome to determine immunophenotypic 
characteristics of the inflammatory infiltrate. We demonstrate that the inflammatory 
infiltrate in skin biopsies is composed of a mixture of histiocytes and immature myeloid 
cells, but also contains significant numbers of plasmacytoid dendritic cells that most likely 
contribute to the pathogenesis of the syndrome by interferon (IFN) secretion.
MATERIALS AND METHODS
Skin biopsies were analyzed from 6 CANDLE syndrome patients, who have been reported 
previously. The syndrome was confirmed by detection of PSMB8 mutations in 5 of them;1-3 
the 6th patient was deceased, but her affected sister had a homozygous PSMB8 mutation. 
For conventional light microscopy, skin biopsies were fixed in 4% formalin, embedded in 
paraffin, cut, and stained with hematoxylin-eosin (H&E). For immunohistochemical studies, 
representative sections of all cases were examined by the alkaline phosphatase anti-alkaline 
phosphatase (APAAP) technique using appropriate positive and negative controls. 
Automated immunostaining was performed on a BioTek Solutions Tech Mate (Tech-Mate 
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500; Biotech Solutions, Dako, Glostrup, Denmark). The antibodies used in this study 
targeted myeloperoxidase (MPO), CD117, CD163, CD68/KP1, CD68/PMG1, CD14, CD15, 
TdT, CD56, CD1a, CD33, CD123, and FoxP3. Their specificities and sources are given in 
Table 1. Chloracetate esterase (LEDER) stain, which stains hematopoietic cells of myeloid 
lineage (and mast cells), was performed in three cases using the Naphthol AS-D 
Chloroacetate (Specific Easterase) Kit from Sigma-Aldrich (91C-1KT) following standard 
laboratory protocols established by the histology section of the Laboratory of Pathology at 
the NIH.
To score the positivity of IHC stains, these were considered negative (−) if no cells were 
stained with the marker; + if the marker was expressed by less than 25 % of the cells in the 
infiltrate; ++ if expressed by 25 % to 50 %; and +++ if it was expressed by 50 % or more of 
the cells in the infiltrate.
RESULTS
H&E-stained sections showed similar histopathologic features, consisting of perivascular 
and interstitial dermal infiltrates extending into the subcutis (Figure 1). The infiltrate was 
mainly composed of mononuclear cells, with many of them exhibiting large, vesicular, 
irregularly shaped nuclei, thus giving the impression of atypical myeloid cells. There were 
also scattered mature neutrophils, a variable number of eosinophils and some mature 
lymphocytes. Leukocytoclasis was often present, but true vasculitis with fibrinoid necrosis 
of the vessel walls was not found.
In all samples, strong and diffuse staining with MPO was observed, revealing that the 
infiltrate was rich in myeloid cells (Figure 2, A,B). A positive LEDER stain performed in 3 
cases further supported the presence of myeloid cells. However, CD15, which is usually 
expressed by mature neutrophils, monocytes and promyelocytes, showed negative results in 
all cases. Interestingly, all samples were also intensely positive for CD68/PMG1 (Figure 3, 
A,B), CD163 (Figure 3, C,D), and CD68/KP1 (not shown), indicating the presence of 
histiocytes and monocytic macrophages. Double-IHC with MPO and CD163 performed in 5 
cases revealed a double population of MPO-positive myeloid cells and CD163-positive 
macrophages (Figure 4).
CD123, which identifies plasmacytoid dendritic cells, was positive in all cases, showing 
clustering of these cells in the infiltrate (Figure 5, A,B). Plasmacytoid dendritic cells are the 
most potent producers of Type I IFN.4 FoxP3 positivity was also noted (not shown), 
indicating the presence of significant numbers of T regulatory cells (Tregs) within the 
infiltrate.5
Numerous CD14 and CD33 were also seen (not shown), further demonstrating an important 
contribution of monocytes to the inflammatory infiltrate. CD117, CD15, TdT, CD56, and 
CD1a were negative (not shown), thus excluding the presence of mast cells, NK cells and 
Langerhans cells, as well as precursor hematological cells. A summary of the IHC results is 
shown in Table 2.
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CANDLE patients have a primary defect in the ubiquitin proteasome system that degrades 
intracellular proteins derived from self or foreign structures and that has a major role in the 
removal of misfolded proteins.6-8 Proteins are marked for destruction by ubiquitination to 
allow their recognition by the proteasome or the immunoproteasome. Certain triggers, such 
as infection or cellular stress, lead to the secretion of type I (IFN-α, −β) and type II (IFN-γ) 
IFNs, that activate the JAK kinase pathway. IFN stimulation produces increased amounts of 
waste proteins.9 PSMB8 missense mutations lead to decreased catalytic activity of the 
immunoproteasome, whereas a PSMB8 nonsense mutation causing premature termination 
codon leads to the inability to assemble the immunoproteasome.3 While the exact 
pathophysiology of CANDLE syndrome is still obscure, it is postulated that hematopoietic 
and likely also non-hematopoietic cells are unable to dispose of the waste proteins and that 
the excess accumulation of ubiquitinated proteins causes further cellular stress. This leads to 
a vicious cycle of cellular stress and further IFN release.
Our results indicate that the inflammatory cutaneous infiltrate in CANDLE syndrome is 
polymorphous and includes a mixture of immature myeloid cells, macrophages, 
plasmacytoid dendritic cells, and Tregs. Therefore, it mirrors the suggested pathophysiology 
of the syndrome. CD123-positive plasmacytoid dendritic cells are triggered to rapidly 
release Type I IFNs,4 and may be an important local population. Cells lacking intact 
proteasome function induce IFN-α (unpublished observations) and can contribute to the 
activation of the JAK kinase pathway and production of proinflammatory mediators. 
Interestingly, most macrophages in the lesional skin biopsies are CD68 and CD163 positive, 
the latter a marker that is more associated with M2-like macrophages, which are involved in 
immunosuppression and constructive tissue remodeling. They inhibit release of 
proinflammatory cytokines, scavenge debris, and promote tissue repair10,11 and may 
represent the “tissue’s attempt” to remodel and resolve the inflammatory lesion, as 
phagocytosis of apoptotic cells is an important role of M2-like macrophages for 
maintenance of cellular homeostasis.12 Alternatively, they may resemble macrophages seen 
in subacute necrotizing lymphadenitis.13 The IFN signatures in the blood of CANDLE 
patients do not allow us to definitively distinguish type I and type II IFN stimulation but are 
in general thought to be more associated with type I IFN.
The other innate immune cell subset found in the tissue, are granulocytes with an immature 
appearance including a non-segmented nuclei that stain with myeloid markers (MPO, 
LEDER stain). It remains unresolved why the granulocytes in the tissue remain immature, 
however an immature granulocyte signature is found in the peripheral blood of systemic 
lupus erythematosus patients together with an IFN signature,14 suggesting that the 
histopathology findings may be consistent with an IFN-mediated process in the skin. 
However, a better understanding of the tissue cytokines and the role of IFNs on the tissue 
migration of granulocytes and monocytes will likely shed light on that phenomenon in the 
future. During disease flares patients develop leukopenia and thrombocytopenia which is 
consistent with the known bone marrow suppressive effects of IFN in line with observations 
that high doses of therapeutically administered IFN-α to patients with hepatitis cause bone 
marrow suppression.15 The recruitment of mononuclear cells into the tissue may be 
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triggered by skin resident cells including fibroblasts and other cells that are stressed in the 
context of IFN. Patients with CANDLE syndrome are unable to upregulate their proteasome 
production in stress situations to keep up with the degradation of “waste proteins” or 
immature proteins that are over-produced in the presence of particularly IFN mediated 
inflammation16 and thus amplify a vicious cycle of more IFN production leading to more 
cell stress and the further recruitment of inflammatory cells into the tissue.
The presence of FoxP3 Tregs in the infiltrate is of unknown pathophysiological significance, 
but can be explained as an attempt to downregulate the cycle of proinflammatory reactions 
and establish tissue homeostasis.
Laboratory studies in CANDLE syndrome support a proposed pathomechanism of IFN-
mediated pathology. In fact, microarray analyses in patients with CANDLE syndrome have 
shown an intense expression of IFN signature genes, and high levels of proteins induced by 
IFN have been reported in the serum of patients with CANDLE syndrome, such as IFN-
derived protein 10.3
To our knowledge, this study is the most comprehensive IHC characterization of the 
cutaneous infiltrate in CANDLE syndrome. It sheds further light on the pathophysiological 
mechanism of the syndrome, and emphasizes its diverse immunological and inflammatory 
responses, which are mostly IFN-derived. The unique combination of histopathologic and 
IHC features presented in this study is virtually pathognomonic of CANDLE syndrome, and 
should permit early diagnosis of the disease, even in the absence of clinical suspicion or 
clinical information. Given that many of the characteristic features of the syndrome, such as 
facial lipodystrophy or prominent abdomen, appear later in the disease course, early 
histopathological recognition allows intervention, such as with the JAK1/2 inhibitor 
baricitinib (and clinical trials are underway, NCT01724580),17 which could prevent severe 
morbidity and mortality.
ACKNOWLEDGMENTS
This work was supported in part by the NIAMS Intramural Research Program (IRP) at the National Institutes of 
Health (NIH); The Authority for Research and Development, Hebrew University of Jerusalem (to A.Z.), and the 
Young clinician’s grant, Hadassah – Hebrew University Medical Center (to Y.R.).
Source of Funding:
This work was supported in part by the NIAMS Intramural Research Program (IRP) at the National Institutes of 
Health (NIH) (to Dr. Raphaela Goldbach-Mansky); The Authority for Research and Development, Hebrew 
University of Jerusalem (to Dr. Abraham Zlotogorski); and the Young clinician’s grant, Hadassah – Hebrew 
University Medical Center (to Dr. Yuval Ramot).
REFERENCES
1. Torrelo A, Patel S, Colmenero I, et al. Chronic atypical neutrophilic dermatosis with lipodystrophy 
and elevated temperature (CANDLE) syndrome. J Am Acad Dermatol. 2010; 62:489–495. 
[PubMed: 20159315] 
2. Ramot Y, Czarnowicki T, Maly A, Navon-Elkan P, Zlotogorski A. Chronic atypical neutrophilic 
dermatosis with lipodystrophy and elevated temperature syndrome: a case report. Pediatr Dermatol. 
2011; 28:538–541. [PubMed: 20553399] 
Torrelo et al. Page 5









3. Liu Y, Ramot Y, Torrelo A, et al. Mutations in proteasome subunit β type 8 cause chronic atypical 
neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and 
phenotypic heterogeneity. Arthritis Rheum. 2012; 64:895–907. [PubMed: 21953331] 
4. Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic 
states. Adv Anat Pathol. 2009; 16:392–404. [PubMed: 19851130] 
5. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor 
Foxp3. Science. 2003; 299:1057–1061. [PubMed: 12522256] 
6. Jung T, Catalgol B, Grune T. The proteasomal system. Mol Aspects Med. 2009; 30:191–296. 
[PubMed: 19371762] 
7. Ciechanover A. Intracellular protein degradation: from a vague idea through the lysosome and the 
ubiquitin-proteasome system and onto human diseases and drug targeting. Neurodegener Dis. 2012; 
10:7–22. [PubMed: 22327508] 
8. Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to 
cancer therapy. Biochem Soc Trans. 2007; 35:12–7. [PubMed: 17212580] 
9. Ebstein F, Kloetzel PM, Krüger E, Seifert U. Emerging roles of immunoproteasomes beyond MHC 
class I antigen processing. Cell Mol Life Sci. 2012; 69:2543–2558. [PubMed: 22382925] 
10. Mosser DM. The many faces of macrophage activation. J Leukoc Biol. 2003; 73:209–212. 
[PubMed: 12554797] 
11. Shabo I, Stål O, Olsson H, Doré S, Svanvik J. Breast cancer expression of CD163, a macrophage 
scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer. 
2008; 123:780–786. [PubMed: 18506688] 
12. Weigert A, Johann AM, von Knethen A, Schmidt H, Geisslinger G, Brüne B. Apoptotic cells 
promote macrophage survival by releasing the antiapoptotic mediator sphingosine-1-phosphate. 
Blood. 2006; 108:1635–1642. [PubMed: 16690965] 
13. Jang SJ, Jeon HM, Kim D, Yang W-I. Myeloperoxidase positive histiocytes in subacute 
necrotizing lymphadenitis express both CD11c and CD163. Basic and Applied Pathology. 2011; 
4:110–115.
14. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and 
granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003; 197:711–723. 
[PubMed: 12642603] 
15. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, Gangl A, 
Ferenci P. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. 
Gastroenterology. 2002; 123:141–151. [PubMed: 12105843] 
16. Krüger E, Kloetzel PM. Immunoproteasomes at the interface of innate and adaptive immune 
responses: two faces of one enzyme. Curr Opin Immunol. 2012; 24:77–83. [PubMed: 22296715] 
17. Almeida de Jesus A, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and 
clinical manifestations. Clin Immunol. 2013; 147:155–174. [PubMed: 23711932] 
Torrelo et al. Page 6










Histopathologic features of CANDLE syndrome. A, Skin sections demonstrating a mixed 
interstitial and perivascular inflammatory infiltrate. B-D, Higher magnification of A, 
revealing abundant atypical myeloid cells combined with mature neutrophils, in addition to 
mature lymphocytes and some eosinophils. Leukocytoclasis is also present. H&E, Original 
magnifications, 10X (A), 20X (B), 40X (C), 100X (D).
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Myeloperoxidase stain for myeloid cells. A, Strong myeloperoxidase positivity reveals the 
presence of cells from a myeloid origin (original magnification, 10X). B, Higher 
magnification of A (40X). MPO: myeloperoxidase.
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Labeling of monocytes. A, CD68/PGM1 immunostain reveals the presence of monocytic 
cells (original magnification, 10X). B, Higher magnification of A (100X). C, positive 
CD163 staining (original magnification, 10X). D, Higher magnification of C (40X).
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Double immunostaining with MPO and CD163 reveals different cell populations co-existing 
in the same skin region. Original magnifications, 10X (A), 40X (B), 40X (C), 100X (D).
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CD123 stain. A, Several foci of plasmacytoid dendritic cells are highlighted by CD123 
(original magnification, 10X). B, Higher magnification of A (40X).
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Table 1
Immunhistochemical markers and special stain used for staining
Monoclonal antibody Source Main cellular expression
CD163 10D6, Menarini, Berlin, Germany Monocytes, macrophages
CD68/KP1 KP1, DAKO, Hamburg, Germany Monocytes, macrophages, myeloid precursors, neutrophils, 
mast cells
CD68/PMG1 PG-M1, DAKO, Hamburg, Germany Monocytes, macrophages
CD14 7, Menarini, Berlin, Germany Monocytes, macrophages
Myeloperoxidase Polyclonal rabbit, DAKO, Hamburg, Germany Neutrophils, monocytes
CD33 PWS44, Menarini, Berlin, Germany Progenitor and other myeloid cells, monocytes
CD15 C3D-1, DAKO, Hamburg, Germany Granulocytes, myeloid leukemia
CD123 7G3, BD Biosciences, Heidelberg, Germany Plasmacytoid dendritic cells
FoxP3 236A/E7, Abcam, Cambridge, UK T regulatory cells
TdT Polyclonal rabbit, DAKO, Hamburg, Germany Immature pre-B and pre-T cells
CD56 RCD56 (rabbit), Zytomed systems, Berlin, Germany NK cells, some leukemias
CD1a 010, DAKO, Hamburg, Germany Langerhans cells
CD117 Polyclonal rabbit, DAKO, Hamburg, Germany Mast cells
LEDER (special stain) 91C-1KT, Sigma-Aldrich, St. Louis, MO, USA Hematopoietic cells of myeloid lineage and mast cells
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Table 2
A summary of all immunohistochemistry stains in the 6 samples studied
Patient 1 2 3 4 5 6
CD163 ++ ++ ++ ++ ++ ++
CD68/KP1 +++ +++ ND ND ND ND
CD68/PMG1 ++ ++ ++ ++ ++ ++
CD14 +++ +++ ++ ++ ++ ++
CD33 ++ ++ +++ ++ ++ +++
MPO +++ +++ +++ +/- ++ +++
LEDER stain + + ++ ND ND ND
CD123 + + + +/− + +
FoxP3 + + ++ − +/− ++
CD15 − − − − − −
TdT − − − − − −
CD56 − − ND ND ND ND
CD1a − − ND ND ND ND
CD117 − − ND ND ND ND
−: negative; +: <25 % of the cells in the infiltrate; ++: 25% − 50 % of the cells in the infiltrate; +++: >50 % of the cells in the infiltrate. ND: Not 
Done
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